Alluvi, previously BI 4744, offers a significant development in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://alluvi-peptides896215.wikissl.com/user